Loading...

Hua Medicine (Shanghai) Ltd.

2552.HK•HKSE
Healthcare
Drug Manufacturers - Specialty & Generic
HK$3.29
HK$-0.14(-4.08%)

Hua Medicine (Shanghai) Ltd. (2552.HK) Stock Overview

Explore Hua Medicine (Shanghai) Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 70.3/100

Key Financials

Market Cap3.2B
P/E Ratio-11.79
EPS (TTM)$-0.27
ROE2.97%
Fundamental Analysis

AI Price Forecasts

1 Week$3.24
1 Month$3.19
3 Months$2.07
1 Year Target$1.13

2552.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Hua Medicine (Shanghai) Ltd. (2552.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 59.68, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.13.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -11.79 and a market capitalization of 3.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

59.68RSI (14)
0.16MACD
27.16ADX
Revenue Growth
234.02%
↑ 234.02%
Profit Growth
HK$-0.25
↓ 18.42%
EPS Growth
HK$-0.25
↓ 13.64%
Operating Margin
-140.80%
↓ 21.98%
ROE
296.67%
↓ 18.42%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 2552.HKAnalyst Recommendations details for 2552.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes. In addition, it is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. The company was incorporated in 2011 and is based in Beijing, China.

CEO

Li Chen

Employees

168

Headquarters

Building A, Shanghai

Founded

2018

Frequently Asked Questions

;